. We recently performed a mutational analysis of a m-AMSA-induced T4 topoisomerase cleavage site (13). We found that nucleotide residues important for enzyme recognition were in the regions flanking the cleavage site (-2 to -6 and -2' to -6'; see Fig. 1A ), while inhibitor-specific preferences were at the base pairs immediately surrounding the cleaved phosphodiester bonds (positions -1, -1' and +1, +1'). Interestingly, the inhibitor-specific preferences found with the T4 enzyme are essentially identical to those found by consensus sequence analysis with the mammalian enzyme (10-15), suggesting that the same rules govern inhibitor binding specificity for evolutionarily distant topoisomerases.
linked to cleaved DNA. We have used 3-azido-AMSA [4'-(3- azido-9-acridinylam)methanesulfon-m-anlsdide], a photoactivatible analog of the inhibitor m-AMSA [4'-(9-acridinylamino)methanesulfon-m anisde, to localize the inhibitor binding site in a cleavage complex consisting of an oligonucleotide substrate and the bacteriophage T4 type II DNA topoisomerase. Upon photoactivation, the inhibitor covaleatly attached to the substrate only in the presence of topoisomerase. Sites of inhibitor attachment were detected by primerextension analysis and by piperidine-induced cleavage of the covalently modified substrate. 3-Azido-AMSA reacted with bases immediately adjacent to the two phosphodiester bonds cleaved by the enzyme. Therefore, topoisomerase creates or stabilizes preferential bidi sites for the inhibitor precisely at the two sites of DNA cleavage.
Type II topoisomerases are ubiquitous enzymes that catalyze important DNA topological interconversions. These interconversions are achieved by a conserved mechanism: the enzyme dimer makes a double-strand break in one helix, passes a second helix through this DNA gate, and religates the double-strand break. A key intermediate in the topoisomerase reaction, the cleavage complex, consists ofeach monomer of the enzyme covalently attached, via a phosphotyrosine bond, to one of the two 5' phosphates of the 4-bp staggered DNA break (1) (2) (3) . This normally short-lived intermediate is stabilized by many different inhibitors that target topoisomerases (4) (5) (6) (7) (8) . The mammalian type II topoisomerase is a target for several classes of antitumor agents, including they aminoacridines, anthracyclines, ellipticines, and epipodophyllotoxins. Similarly, the antibacterial quinolones target the bacterial type II topoisomerase, DNA gyrase. For both the antitumor and antibacterial agents, cell death is dependent on stabilization ofthe cleavage complex (a form of DNA damage) rather than loss of topoisomerase activity (4) (5) (6) (7) .
The simplest general model to explain stabilization of the cleavage complex is that the inhibitors bind to DNA at or near the cleaved phosphodiester bonds, preventing DNA religition. Based on quinolone binding to-single-stranded DNA, Shen et al. (9) proposed that quinolones bind to the 4-bp denatured region between the gyrase-cleaved bonds. For the mammalian and bacteriophage T4 enzymes, the identity of the base pairs directly adjacent to the cleaved phosphodiester bonds determines which inhibitors stabilize DNA cleavage, arguing that the inhibitors bind in the vicinity of each cleaved bond, perhaps by intercalation (7, (10) (11) (12) (13) (14) (15) (19, 20) . Second, a single mutational alteration of the T4 type II topoisomerase simultaneously altered inhibitor sensitivity (i.e., interaction with inhibitor) and DNA cleavage site specificity (i.e., interaction with DNA) (21) .
The bacteriophage T4-encoded type II topoisomerase is sensitive to many antitumor agents that inhibit the mammalian enzyme, including m-AMSA [4'-(9-acridinylamino)methanesulfon-m-anisidide], and thereby provides a good model system (22) . We recently performed a mutational analysis of a m-AMSA-induced T4 topoisomerase cleavage site (13) . We found that nucleotide residues important for enzyme recognition were in the regions flanking the cleavage site (-2 to -6 and -2' to -6'; see Fig. 1A ), while inhibitor-specific preferences were at the base pairs immediately surrounding the cleaved phosphodiester bonds (positions -1, -1' and +1, +1'). Interestingly, the inhibitor-specific preferences found with the T4 enzyme are essentially identical to those found by consensus sequence analysis with the mammalian enzyme (10) (11) (12) (13) (14) (15) , suggesting that the same rules govern inhibitor binding specificity for evolutionarily distant topoisomerases.
In the present study, we have localized the sites ofinhibitor binding in the topoisomerase-DNA complex by more direct means using 3-azido-AMSA [4'-(3-azido-9-acridinylamino)methanesulfon-m-anisidide], a photoactivatible analog of m-AMSA. 3-Azido-AMSA was synthesized by Shieh et al. (23) and found to have DNA binding properties similar to those of m-AMSA. Most importantly for our purposes, photoactivation of 3-azido-AMSA in the presence of either deoxyribonucleosides or DNA produces covalent drug-DNA adducts (23) . Covalent linkage of 3-azido-AMSA to a DNA substrate during a topoisomerase cleavage reaction allowed us to precisely localize the bound inhibitor after removal of the enzyme.
MATERIALS AND METHODS
Topoisomerse and Inhibitors. T4 topoisomerase was purified as described (21, 24 (25, 26) and resuspended in lx TE (10 mM (13) . Several base substitutions that increased the efficiency of m-AMSA-induced cleavage were combined to generate a new 38-bp oligonucleotide substrate (Fig. 1A) . Topoisomerase-mediated cleavage of this substrate in the presence of m-AMSA was severalfold more efficient than the original substrate (data now shown).
The 38-bp 5'-end-labeled substrate was cleaved in the presence of T4 topoisomerase and either m-AMSA or 3-azido-AMSA, generating the expected 16-and 18-base products upon denaturation (Fig. 1B) . Furthermore, 3-azido-AMSA induced cleavage at this site with a potency indistinguishable from that of m-AMSA (Fig. 1C) . We conclude that 3-azido-AMSA is an effective inhibitor of the T4 topoisomerase, with DNA site specificity and potency similar or identical to m-AMSA.
Localization of the Inhibitor by Primer Extension. The first method we used to locate covalently bound 3-azido-AMSA was primer extension. Duplex 38-mer oligonucleotide was incubated with T4 topoisomerase in the presence of 3-azido-AMSA, with UV light to activate the azido group. The reaction products were purified and heat denatured, and a labeled 9-base primer with either the top-strand sequence or the bottom-strand sequence was annealed and extended with Klenow polymerase.
When the reaction products had been generated with 3-azido-AMSA and UV light but no topoisomerase, extension proceeded predominantly to full-length product ( Fig.  2A) . The faint bands present at each nucleotide position were also detected without 3-azido-AMSA and UV light (data not shown). Thus, in the absence of topoisomerase, no 3-azido- 7 primer 22 23 A C -- AMSA binding sites were stable enough to be detected by this method. When the reaction products had been generated with topoisomerase and 3-azido-AMSA but no UV light, the expected runoff products due to topoisomerase cleavage were readily detected (top-strand primer, 20 bases; bottomstrand primer, 22 bases). An additional extension product formed a band 1 base larger than each of the topoisomerase runoff products. We attribute this band to untemplated base addition as described (13, 26, 28) . This interpretation was confirmed by extending the top-strand primer annealed to an oligonucleotide that was synthesized to mimic the bottomstrand topoisomerase cleavage product (bottom strand, A-19-C-38); both the 20-and 21-base products were generated (data not shown).
When the reaction products had been generated with topoisomerase and 3-azido-AMSA in the presence of UV light, the runoffproducts due to topoisomerase cleavage were again detected, along with novel bands that apparently result from photoactivation of 3-azido-AMSA ( Fig. 2A) . Using the top-strand primer, a strong extension stop was detected at 16 bases, along with a weaker stop at 17 bases. Similarly, with the bottom-strand primer, a strong stop was detected at 18 bases and a weaker one was detected at 19 bases. Generation of these novel products was dependent on the presence of topoisomerase, 3-azido-AMSA, and UV light ( Fig. 2A ; data not shown). We interpret the strong primer-extension stop on each strand (top-strand primer, 16 bases; bottom-strand primer, 18 bases) as a block to further elongation due to covalent modification of the next template base. Thus, 3-azido-AMSA molecules apparently reacted with T-22 on the bottom strand and with T-20 on the top strand, symmetrical positions with respect to the phosphodiester bonds cleaved by topoisomerase (Fig. 2B) .
We believe that the weaker stop on each stand (top-strand primer, 17 bases; bottom-strand primer, 19 bases) is due to an untemplated base addition, as detected above at the topoisomerase cleavage site. We cannot eliminate the possibility that the primer was blocked for further elongation due to covalent modification of the next template base (bottom strand, A-21; top strand, A-19; see Fig. 2B ). However, a second method showed no evidence for 3-azido-AMSA modification at these positions (see below).
Photoactivation of 3-Azido-AMSA Usng End-Labeed Substrates. We next sought to directly locate sites of 3-azido-AMSA modification on 5'-end-labeled 38-bp substrates. Topoisomerase reaction mixtures contained either 3-azido-AMSA (under UV light) or m-AMSA (as a control). Duplicate reactions were subjected to heat treatment (650C for 10 min), which reverses most topoisomerase cleavage products (29) . Both 3-azido-AMSA and m-AMSA induced the expected strong cleavage products, along with several faint bands representing weaker cleavage sites (Fig. 3) . As expected, a large fraction of the cleavage products was reversed by heat treatment (Fig. 3, A) . Two novel bands (Fig. 3, *) were detected only from the 3-azido-AMSA reactions; each ran slightly faster than one of the major cleavage products. Unlike topoisomerase cleavage products, these products were detected only with UV light and were not reversed by heat treatment (Fig. 3; data not shown) . By testing substrates with only one strand labeled, the smaller photoactivation product was shown to originate from the top strand and the larger one was shown to originate from the bottom strand (Fig. 3) . (23) found that 3-azido-AMSA modification ofa base can result in cleavage of the N-glycosidic bond. Lcalization of the Inhibitor by Piperidine Cleavage. In Maxam-Gilbert sequencing reactions, sites of base-specific modification are cleaved by piperidine treatment (27) . We reasoned that sites of 3-azido-AMSA modification could be precisely located if they are also sensitive to piperidine. Therefore, the above reactions were repeated with and without piperidine treatment, and the products were run next to Maxam-Gilbert sequencing standards of the same DNA. Upon treatment with piperidine, the nonreversible band associated with the top-strand cleavage product disappeared, and a new band appeared, comigrating with sequencing standard T-16 (Fig. 4A, lanes 1-4) . This piperidine cleavage product required topoisomerase, was not detected in m-AMSA-containing control reaction mixtures, and was not reversed by prior heat treatment ( Fig. 4A ; data not shown). We conclude that a photoactivated 3-azido-AMSA modification existed at position T-16, and that piperidine cleaved Fig. 3 , except that duplicate reaction products were treated with piperidine (+; after topoisomerase cleavage and heat reversal) to effect strand cleavage at modified bases. Topoisomerase cleavage products (arrows) and nonreversible bands (*) are indicated on the left. Sizes of piperidine cleavage products are indicated on the right; size determination was by comparison with Maxam-Gilbert sequencing products. Topoisomerase cleavage products end with a 3' hydroxyl, while piperidine cleavage products end with a 3' phosphate and thereby migrate slightly faster. (B) Reactions were the same as in A, except that the 38-bp substrate was labeled at the 3' end on either the top strand (Top) or bottom strand (Bot). Topoisomerase cleavage products are indicated by arrows. The top-strand piperidine cleavage product comigrated with top-strand sequencing standard T-20 (a 19-base product) and the bottom-strand product comigrated with sequencing standard T-22 (a 17-base product; standards generated by Maxam- Gilbert sequencing of the same 3'-end-labeled oligonucleotides). (C) Summary of residues cleaved by piperidine after photoactivation with 3-azido-AMSA (boxed).
the phosphodiester backbone at that position. Very similar results were obtained when the bottom strand ofthe substrate was labeled; in this case, the piperidine cleavage product comigrated with T-18 ( Fig 4A, lanes 5-8) . Therefore, upon photoactivation, 3-azido-AMSA covalently modified two symmetrical positions in the topoisomerase cleavage site: T-16 on the top strand and T-18 on the bottom strand (see Fig.  4C ).
Longer products were also detected upon piperidine treatment of 3-azido-AMSA reactions that had been heat reversed (Fig. 4A) . The top-strand product comigrated with sequencing standard T-20 (lane 4) and the bottom-strand product comigrated with T-22 (lane 8). We conclude that bases T-20 (top strand) and T-22 (bottom strand) were covalently modified by photoactivated 3-azido-AMSA. These longer products were detected only after heat reversal, implying that they originated from substrates that had been cleaved by topoisomerase but resealed with heat treatment. This interpretation was confirmed by repeating the experiment with substrates containing 3' end labels (Fig. 4B) . In this case, the topoisomerase cleavage products migrated as a series of bands, presumably because of variable amounts of residual topoisomerase that survived proteinase K treatment. The strongest 3-azido-AMSA-induced piperidine-dependent products comigrated with sequencing standards T-20 (top strand) and T-22 (bottom strand) (Fig. 4B ). These two positions agree precisely with the assignments made from the 5'-end-labeled substrates and with those determined by primer extension (see above).
In summary, four sites of 3-azido-AMSA modification have been located by piperidine cleavage, and the two strongest of these were also detected by primer extension ( Fig. 4C; This study demonstrates that the inhibitor binding site in a topoisomerase-DNA complex is in the immediate vicinity of the cleaved phosphodiester bonds. Four nucleotide residues of a strong topoisomerase cleavage site are in close contact with the inhibitor, and all four are within the base pairs immediately adjacent to the cleaved phosphodiester bonds. The same pattern of 3-azido-AMSA modification was also detected at another strong T4 topoisomerase cleavage site (unpublished data). Given the close similarities between the T4 and mammalian enzymes and the common drugdependent sequence preferences at cleavage sites (see Introduction), the location ofthe drug binding site in both enzyme-DNA complexes is likely to be the same.
The photoactivatible inhibitor reacted with only one residue of each of the 4 base pairs adjacent to the cleaved phosphodiester bonds, suggesting that the orientation of the inhibitor is most favorable for the activated azido group to react with these residues. The lack of reactivity at the complementary residues is not due to the fact that they are adenines instead of thymines; substitution of either A-17 (top strand) or A-23 (bottom strand) with thymine did not result in reactivity (even though cleavage was not significantly reduced; unpublished data).
All four of the reactive bases that we detected in the cleavage complex are thymines; however, Shieh et al. (23) detected covalent photoadducts of 3-azido-AMSA with free dA, dG, and dC nucleosides. To investigate the base specificity of photoactivation, we substituted the reactive T-22 (bottom strand) with A, G, or C, and monitored 3-azido-AMSA modification in the presence of topoisomerase by primer extension. We found reactivity with both G and C but not with A (unpublished data). Therefore, 3-azido-AMSA can react with 3 of the 4 possible nucleotide residues providing they are in the correct position within the cleavage complex.
Many of the type II topoisomerase inhibitors, including m-AMSA and 3-azido-AMSA, are DNA intercalators and therefore bind to sites in nakdd DNA (6, 8, 23 (22, 30, 31) .
The binding site for the quinolones probably also involves DNA at the active site of DNA gyrase (19, 20) . In the model of Shen et al. (9) , the inhibitor binding site is created by denaturation of the 4-bp region between the cleaved bonds, with the inhibitor binding preferentially to the internal bases (positions +2 and +2'). However, oxolinic acid-induced cleavage sites for DNA gyrase and for the T4 topoisomerase show base preferences at positions adjacent to the cleaved bonds rather than at the internal bases (13, 32, 33) . Thus, the quinolones may also bind at the sites of phosphodiester bond cleavage, perhaps in a manner much like intercalators such as m-AMSA.
Finally, mammalian type I topoisomerase is the target for the antitumor drug camptothecin. Analysis of DNA cleavage sites for that enzyme revealed a strong camptothecin-induced preference for G immediately 3' to the cleaved phosphodiester bond (34) . Furthermore, photoactivation of camptothecin in the absence of topoisomerase generated lesions exclusively at G residues (35) . Thus, camptothecin apparently traps cleavage complexes at sites with a 3' G by interacting directly with the G-C base pair (35) .
In summary, the inhibitor binding sites in the cleavage complexes of diverse topoisomerases are likely to be closely related. Previous studies provided many indirect arguments that the inhibitors bind to DNA at the active sites of topoisomerases, presumably inhibiting DNA religation. The results presented here provide direct evidence that localizes the inhibitor binding site within a cleavage complex. Inhibitor binding in the immediate vicinity of the cleaved phosphodiester bond, perhaps by intercalation into that internucleotide space, is likely the common mechanism for inhibition of diverse topoisomerases.
